Polaryx Therapeutics entered into a Securities Purchase Agreement for a private placement of 2,502,696 shares of common stock. The financing raised $10 million in aggregate gross proceeds. The weighted average price per share for the offering was approximately $4.00. Proceeds are earmarked for the Phase 2 SOTERIA basket trial (PLX-200-600), working capital, and general corporate purposes. The company expects this capital to extend its operating runway through the second quarter of 2027.